Evidence map›Paper›PMID 33557673›Full record

ArticlemAbs

Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody.

Sharon M Campbell, Joseph DeBartolo, James R Apgar, Lydia Mosyak, Virginie McManus, Sonia Beyer, Eric M Bennett, Matthew Lambert, Orla Cunningham

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Reconstruction of full antibody sequences in NGS datasets and accurate VComputational and structural biotechnology journal · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sharon M CampbellBiomedicine Design, Pfizer , Dublin, Ireland.
Joseph DeBartoloBiomedicine Design, Pfizer , Cambridge, MA, USA.
James R ApgarBiomedicine Design, Pfizer , Cambridge, MA, USA.
Lydia MosyakBiomedicine Design, Pfizer , Cambridge, MA, USA.
Virginie McManusBiomedicine Design, Pfizer , Dublin, Ireland.
Sonia BeyerBiomedicine Design, Pfizer , Dublin, Ireland.
Eric M BennettBiomedicine Design, Pfizer , Cambridge, MA, USA.
Matthew LambertBiomedicine Design, Pfizer , Dublin, Ireland.
Orla CunninghamBiomedicine Design, Pfizer , Dublin, Ireland.ORCID 0000-0002-3888-9541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial technological advances in antibody library and display platform development, the number of approved biotherapeutics from displayed libraries remains limited.

Indexed as

Drug DesignHigh-Throughput Nucleotide SequencingMutagenesisProtein EngineeringAntibodies, NeutralizingAntibody SpecificityComputer-Aided DesignDrug StabilityHEK293 CellsHumansInterleukin-21 Receptor alpha SubunitProtein ConformationProtein StabilityStructure-Activity RelationshipAntibodies, NeutralizingIL21R protein, humanInterleukin-21 Receptor alpha SubunitAntibody nonspecificitydeselectiondevelopabilityIL-21Roptimization

Identifiers

PMID33557673
PMCPMC7889167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.